Atea Pharmaceuticals’ (AVIR) Outperform Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Atea Pharmaceuticals (NASDAQ:AVIR) in a research note released on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals’ Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ AVIR opened at $2.99 on Friday. The firm has a market capitalization of $252.54 million, a price-to-earnings ratio of -1.44 and a beta of 0.18. The stock has a 50 day moving average price of $3.15 and a 200 day moving average price of $3.34. Atea Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $4.18.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Analysts forecast that Atea Pharmaceuticals will post -2.01 earnings per share for the current year.

Insiders Place Their Bets

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 17.80% of the stock is owned by company insiders.

Institutional Trading of Atea Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at $37,000. Graham Capital Management L.P. purchased a new stake in shares of Atea Pharmaceuticals during the 4th quarter valued at $42,000. Millennium Management LLC purchased a new stake in shares of Atea Pharmaceuticals during the 4th quarter valued at $75,000. Finally, Zacks Investment Management purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter valued at $80,000. Hedge funds and other institutional investors own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.